An infectious disease of colon, recurrent Clostridium difficile infection (RCDI) is hitherto considered
insurmountable leading to significant morbidity and mortality. Gut dysbiosis, generally resulting from frequent use of
antibiotics is considered to be responsible for the etiopathogenesis of rCDI. Ironically, the conventional treatment
strategies for the disease also include the use of anti-infective drugs such as metronidazole, vancomycin and fidaxomycin.
As a result of the efforts to overcome the limitations of these treatment options to control recurrence of disease, Fecal
Microbiota Transplant (FMT) has emerged as an effective and safe alternative. It is pertinent to add here that FMT is
defined as the process of engraftment of fecal suspension from the healthy person into the gastrointestinal tract of the
diseased individual aiming at the restoration of gut microbiota. FMT has proved to be quite successful in the treatment of
recurrent and resistant Clostridium difficile infections (RCDI). In last three decades a lot of information has been
generated on the use of FMT for RCDI. A number of clinical trials have been reported with generally very high success
rates. However, very small number of patents could be found in the area indicating that there still exists lacuna in the
knowledge about FMT with respect to its preparation, regulation, mode of delivery and safety. The current review
attempts to dive deeper to discuss the patents available in the area while supporting the information contained therein with
the non-patent literature.
Keywords: Fecal microbiota transplantation, recurrent clostridium difficile, antibiotics, metronidazole, microbiota, dysbiosis
Rights & PermissionsPrintExport